论文部分内容阅读
目的：研究阿罗格螨变应原皮下特异性免疫治疗慢性荨麻疹的疗效及安全性。方法选取2012年1月至2012年12月就诊的慢性荨麻疹患者，首先行皮肤点刺试验，纳入以粉尘螨或屋尘螨为主要变应原的患者120例，采用计算机数字表的方法随机分为两组，试验组（60例）给予螨变应原皮下特异性免疫治疗结合基础抗组胺药物对症治疗，对照组（60例）仅给予抗组胺药物对症治疗。1年及2年后观察疗效。结果治疗1年、2年后，试验组有效率分别为61.7%、80.0%。对照组分别为51.7%、61.7%。治疗1年时两组比较差异未见统计学意义，治疗2年时两组比较差异有统计学意义（P ﹤0.05）。两组均未发生严重不良反应。结论螨变应原皮下特异性免疫治疗对于确定尘螨过敏的慢性荨麻疹患者能缓解症状，疗效持久且安全，值得临床推广。“,”Objective To investigate the efficacy and safety of subcutaneous immune therapy on chronic urticaria. Methods From January 2012 and December 2012,one hundred and twenty patients with chronic urticaria were screened out by skinprick test. The patients who had an allergy to dermatophagoides farinae or dermatophagoides pteronyssinus were randomly di-vided into two groups. Observation group(60 cases)was treated with subcutaneous immune therapy and regular antihistamines. Control group(60 cases)was only treated with regular antihistamines. To observe the effect after one year and two years. Results The effective rate was 61. 7% and 80. 0% in observation group,and 51. 7% and 61. 7% in control group at 1 year and 2 years after treatment respectively. The effective rate of two groups showed significant difference at 2 years after treatment but no significant difference at 1 year after treatment. No adverse reaction was found in either group. Conclusion It is effective and safe for the treatment of chronic urticaria with subcutaneous immune therapy.